Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingre Tongluo Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine) for the treatment of refractory rheumatoid arthritis (RRA). The decoction is formulated based on the TCM principle of clearing heat and unblocking the collaterals to address the 'Damp-Heat' and 'Blood Stasis' patterns often observed in chronic joint inflammation. It functions primarily by modulating the immune system and suppressing the inflammatory cascade. Research indicates that the decoction reduces the levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), while also regulating the Th17/Treg cell balance and inhibiting the NF-κB signaling pathway. It is typically used as an adjunctive therapy for patients who show an inadequate response to standard disease-modifying antirheumatic drugs (DMARDs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingre tongluo decoction.